Dane Leone
Stock Analyst at Raymond James
(1.21)
# 3,740
Out of 5,154 analysts
69
Total ratings
33.96%
Success rate
-5.57%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $9.89 | +92.11% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $6 → $4 | $0.53 | +654.72% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.65 | +420.23% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $98.40 | -69.51% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $759.86 | +25.02% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.50 | +420.00% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $65.36 | -29.62% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.92 | +109.60% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.51 | +45.19% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $10.27 | +36.32% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $11.32 | +412.37% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $12.22 | +472.83% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.30 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $60.41 | +4.29% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $60.29 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.99 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $73.26 | -11.27% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $369.53 | -30.99% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.90 | +720.51% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $240.40 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $9.89
Upside: +92.11%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $6 → $4
Current: $0.53
Upside: +654.72%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.65
Upside: +420.23%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $98.40
Upside: -69.51%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $759.86
Upside: +25.02%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.50
Upside: +420.00%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $65.36
Upside: -29.62%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.92
Upside: +109.60%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.51
Upside: +45.19%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $10.27
Upside: +36.32%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $11.32
Upside: +412.37%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $12.22
Upside: +472.83%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.30
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $60.41
Upside: +4.29%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $60.29
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.99
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $73.26
Upside: -11.27%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $369.53
Upside: -30.99%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.90
Upside: +720.51%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $240.40
Upside: -